دورية أكاديمية
Novel strategies exploiting interleukin-12 in cancer immunotherapy.
| العنوان: | Novel strategies exploiting interleukin-12 in cancer immunotherapy. |
|---|---|
| المؤلفون: | Cirella A; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Luri-Rey C; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Di Trani CA; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Teijeira A; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IDISNA), Pamplona, Spain; Department of oncology, Clinica Universidad de Navarra, Madrid, Spain., Olivera I; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Bolaños E; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Castañón E; Department of oncology, Clinica Universidad de Navarra, Madrid, Spain., Palencia B; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain., Brocco D; Department of Pharmacy, University 'G. D'Annunzio' Chieti-Pescara, Chieti, Italy., Fernández-Sendin M; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Aranda F; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Berraondo P; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IDISNA), Pamplona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain., Melero I; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IDISNA), Pamplona, Spain; Department of oncology, Clinica Universidad de Navarra, Madrid, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain; Department of Immunology and immunotherapy, Clínica Universidad de Navarra, Pamplona, Spain. Electronic address: imelero@unav.es. |
| المصدر: | Pharmacology & therapeutics [Pharmacol Ther] 2022 Nov; Vol. 239, pp. 108189. Date of Electronic Publication: 2022 Apr 14. |
| نوع المنشور: | Journal Article; Review; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Pergamon Press Country of Publication: England NLM ID: 7905840 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-016X (Electronic) Linking ISSN: 01637258 NLM ISO Abbreviation: Pharmacol Ther Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Oxford, Elmsford, N. Y., Pergamon Press. |
| مواضيع طبية MeSH: | Interleukin-12*/genetics , Neoplasms*/therapy, Humans ; Immunotherapy/methods ; Genetic Vectors ; Immunotherapy, Adoptive ; Immunologic Factors |
| مستخلص: | Interleukin-12 is considered a potent agent to enhance antitumor immune responses. It belongs to a family of heterodimeric cytokines with key roles in the up-regulation and down-regulation of cellular immunity. Since its discovery, recombinant IL-12 was found to exert potent antitumor effects in rodent tumor models and was rapidly tested in the clinic with an unfavorable benefit/toxicity profile. Localized delivery of IL-12 dramatically improves the therapeutic index and this approach is being applied in the clinic based on in-vivo electroporation of naked plasmid DNA encoding IL-12, mRNA formulations, viral vectors and tumor-targeted fusion proteins. Other biotechnology strategies such as IL-12-engineered local adoptive cell therapy and pro-cytokines can also be used to improve results and broaden the therapeutic window. Combination strategies of such localized IL-12-based approaches with checkpoint inhibitors are yielding promising results both preclinically and in the early-phase clinical trials. (Copyright © 2022 Elsevier Inc. All rights reserved.) |
| فهرسة مساهمة: | Keywords: Adoptive T cell therapy; And RNA-mediated delivery; Expression plasmids; Fusion proteins; Interleukin-12; Localized delivery; Viral vectors |
| المشرفين على المادة: | 187348-17-0 (Interleukin-12) 0 (Immunologic Factors) |
| تواريخ الأحداث: | Date Created: 20220417 Date Completed: 20221108 Latest Revision: 20221109 |
| رمز التحديث: | 20231215 |
| DOI: | 10.1016/j.pharmthera.2022.108189 |
| PMID: | 35430292 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1879-016X |
|---|---|
| DOI: | 10.1016/j.pharmthera.2022.108189 |